Lumisys targets small-scale niche with bundled miniPACS/CR deviceFirm will establish direct sales force to market iLuminatorThe growing interest in PACS among small hospitals, clinics, and private practices has prompted the introduction
Firm will establish direct sales force to market iLuminator
The growing interest in PACS among small hospitals, clinics, and private practices has prompted the introduction of another miniPACS product. Film digitizer and computed radiography vendor Lumisys has launched iLuminator, a bundled, low-cost, standalone miniPACS and computed radiography device that is based on the firms ACR-2000 desktop CR system.
iLuminator combines image acquisition, high-resolution gray-scale display, Internet-based telecommunications, WAN and LAN network capabilities, and DICOM-compliant archiving in a cart-based system that sells for less than $75,000. It is designed for private radiology, orthopedic, and surgical practices; remote clinics; ICUs; emergency rooms; and radiation therapy centers.
In fact, iLuminators compact design and standalone capabilities, combined with the target customer base, have prompted the Sunnyvale, CA-based company to establish a direct sales force for the first time in the firms history. Lumisys is currently recruiting salespeople to market iLuminator in most major cities.
In the past, we sold our digitizers initially with no software layer, said Dr. Phillip Berman, Lumisys president and CEO. Even the ACR-2000, while a finished product with an application layer, still requires somebody to provide a DICOM viewer and DICOM archive. But iLuminator is different by its nature. It has acquisition, viewing, and storage all on a single cart, and doesnt even have to be attached to a HIS.
Berman is hoping the new product and additional sales channel will bolster revenues in coming quarters. A slowdown in bulk sales of the ACR-2000, lower than expected film digitizer sales, and startup costs related to its new Internet business, AuntMinnie.com, put a damper on the firms third-quarter financials. Lumisys reported revenues of $3.9 million for the third quarter (end-September), a 16.7% dip compared with revenues of $4.6 million for the same quarter a year ago. Net loss was $522,000, compared with profit of $176,000 for the third quarter of 1998. This represents the companys first operating loss in seven quarters.
Although several large-quantity sales of the ACR-2000 CR system were pending, they did not close in the third quarter as expected, according to Berman. Small-unit sales have been shipping consistently, however, throughout the four quarters Lumisys has been selling the ACR-2000, Berman said.
Berman believes the decline in bulk orders is a temporary situation. In fact, sales of the ACR-2000 are well above what the company projected when the product was first introduced at last years RSNA meeting, he said. More than 150 systems have been sold to date, and several large orders are pending. Lumisys markets the ACR-2000 through OEM relationships with Brit Systems, DR Systems, Picker International, Swissray International, Analogic, and DeJarnette Research Systems.
In other news, Lumisys has entered into an agreement with GE Healthcare Services. GE will provide on-site services for both the ACR-2000 and iLuminator products.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.